{"nct_id":"NCT04139317","title":"Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%","status":"TERMINATED","status_verified_date":"2024-10","start_date":"2020-01-22","start_date_type":"ACTUAL","primary_completion_date":"2022-01-14","primary_completion_date_type":"ACTUAL","completion_date":"2023-02-07","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["NVS"]}